<<Frosty: Although milestone payments and partnership agreements are positive actions, Rx specification, sales and earnings are the true drivers of future stock prices and higher EPS.>>
Couldn't agree more. Additionally, events like milestone payments trigger interest and develop speculation regarding the potential of a company. I remember buying Vivus at $50 prior to the split, and prior to the FDA approval, plant approval, and before a single Muse package hit any shelf. The price at that time was driven by the interest in male ED products. When Vivus is tagged as a recognized player in the female SD arena, I look for a similar level of interest which may translate into share increase, again,...before FDA approval, marketing, or sales has even started. The continued growth by the company in the interim may be positive as you have suggested. I can wait.
Also, I appreciate your recent contributions. You're beginning to sound like someone who might be looking for an entry point.
Frostman
|
